Article
Biochemistry & Molecular Biology
Pin Gong, Shan Yue, Fuxiong Shi, Wenjuan Yang, Wenbo Yao, Fuxin Chen, Yuxi Guo
Summary: In this study, we investigated the protective effect of Astragaloside IV (Ast) on mouse podocytes and its possible mechanism of action. The results showed that Ast can reduce cell mortality, decrease malondialdehyde (MDA) content and increase superoxide dismutase (SOD) activity, mitochondrial membrane potential, as well as improve the expression of podocyte structure and functional proteins.
Review
Medicine, Research & Experimental
Yiwei Gao, Xin Su, Taiqi Xue, Ning Zhang
Summary: Chinese herbal monomers have been found to attenuate diabetic kidney disease (DKD) in multiple ways. Astragaloside IV (AS-IV), an active ingredient of Astragalus membranaceus, shows promise as a novel drug for DKD treatment. AS-IV improves DKD by combating oxidative stress, attenuating endoplasmic reticulum stress, regulating calcium homeostasis, alleviating inflammation, improving vascular function, and inhibiting epithelial to mesenchymal transition.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Chemistry, Medicinal
Ziyu Li, Wei Yang, Yong Yang, Jianbo Wu, Pei Luo, Yong Liu
Summary: LS-102 effectively suppresses inflammatory responses in adipose stem cells, reduces body weight, improves fat tissue inflammation, and provides protective effects in an obesity-related nephropathy model, outperforming astragaloside IV at the same concentration.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Review
Immunology
Wenbin Liu, Guangrui Huang, Hongliang Rui, Jie Geng, Haikun Hu, Yujiao Huang, Guiyang Huo, Baoli Liu, Anlong Xu
Summary: Membranous nephropathy (MN) is a common pattern of glomerular injury in multiple autoimmune responses. Detecting autoantibodies can lead to personalized precision medicine. Further identification of autoantibodies and biomarkers is needed to accurately predict disease prognosis and therapeutic response.
AUTOIMMUNITY REVIEWS
(2022)
Article
Urology & Nephrology
Isabelle Ayoub, John P. Shapiro, Huijuan Song, Xiaolan Lily Zhang, Samir Parikh, Salem Almaani, Sethu Madhavan, Sergey Brodsky, Anjali Satoskar, Cherri Bott, Lianbo Yu, Michael Merchant, John Klein, Juan M. Mejia-Vilet, Tibor Nadasdy, Dan Birmingham, Brad H. Rovin
Summary: The study indicates a close association between complement activation and the pathogenesis of membranous nephropathy (MN), with significantly higher levels of complement in patients with MN compared to normal controls, and lower levels of the complement regulator CR1. Levels of urine Ba, CSa, and MAC were also found to be correlated with the disease.
KIDNEY INTERNATIONAL REPORTS
(2021)
Article
Endocrinology & Metabolism
Chunmiao Chen, Pingping Liu, Guozhe Zhang
Summary: ASV exerts protective effects against cell damage induced by high glucose by downregulating NFAT5 and inactivating the Notch/Snail pathway.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2023)
Article
Urology & Nephrology
Yuchao Zhao, Meishun Cai, Zhenbin Jiang, Bao Dong, Yu Yan, Yina Wang, Li Zuo
Summary: This study investigates the role of PLA2R and MBL in the pathogenesis of idiopathic membranous nephropathy (iMN) and atypical membranous nephropathy (aMN). The results show that anti-PLA2R (+) patients have higher levels of proteinuria and lower levels of serum albumin, and MBL levels are significantly higher in anti-PLA2R (+) patients in the aMN group.
Article
Urology & Nephrology
Ozgur Akin Oto, Erol Demir, Safak Mirioglu, Ahmet Burak Dirim, Yasemin Ozluk, Egemen Cebeci, Taner Basturk, Ali Riza Ucar, Lala Soltanova, Kanan Nuriyev, Isin Kilicaslan, Halil Yazici, Yasar Caliskan
Summary: This study found that the extent of glomerular C3 deposition is associated with the development of kidney failure in patients with primary membranous nephropathy. Patients with high intensity C3 deposition had lower eGFR, higher proteinuria, and were more likely to experience kidney failure compared to those with low intensity C3 deposition.
JOURNAL OF NEPHROLOGY
(2021)
Article
Urology & Nephrology
Shuang Gao, Zhao Cui, Ming-hui Zhao
Summary: This study investigates the role of C3a and C3a receptor (C3aR) in the pathogenesis of primary membranous nephropathy (MN). It demonstrates that C3a anaphylatoxin is a crucial effector of complement-mediated podocyte damage in MN, and blocking C3aR may be a potentially viable treatment for this disease.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yingjun Zang, Shuang Liu, Aili Cao, Xiangyu Shan, Wenjuan Deng, Zhijun Li, Hao Wang, Yunman Wang, Li Wang, Wen Peng
Summary: The study demonstrates that AS-IV inhibits palmitic acid-induced podocyte apoptosis by regulating calcium ion concentration, protecting the kidneys from diabetic nephropathy. This protective effect is dependent on the inhibition of TRPC6-mediated calcium influx and subsequent coordination of cellular calcium disturbance.
MOLECULAR BIOLOGY REPORTS
(2021)
Article
Urology & Nephrology
Nicola M. Tomas, Annabel Schnarre, Silke Dehde, Renke Lucas, Irm Hermans-Borgmeyer, Oliver Kretz, Sarah M. S. Koellner, Thorsten Wiech, Friedrich Koch-Nolte, Larissa Seifert, Tobias B. Huber, Gunther Zahner
Summary: The study successfully generated a reliable animal model of membranous nephropathy (MN) by expressing a chimeric PLA2R1 in mouse podocytes. This model exhibits clinical characteristics and glomerular alterations similar to human MN, providing an important tool for studying the pathogenesis and treatment of MN.
KIDNEY INTERNATIONAL
(2023)
Article
Pharmacology & Pharmacy
Caiqiong Liu, Xiaoyan Li, Lanjun Shuai, Xiqiang Dang, Fangrong Peng, Mingyi Zhao, Shiqiu Xiong, Ying Liu, Qingnan He
Summary: The study revealed that AS-IV could inhibit Gd-IgA1 secretion via miR-98-5p, and increased levels of miR-98-5p in pediatric IgAN patients might affect the glycosylation of IgA1 by targeting C1GALT1. Additionally, the pathogenesis of IgAN may differ from that of IgAV-N, providing significant insight into potential therapeutic targets.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Takahiro Kanai, Takane Ito, Jun Aoyagi, Takanori Yamagata
Summary: This study reminds us of the existence of membranous nephropathy without vacuolated podocytes in Fabry disease during treatment.
Article
Pharmacology & Pharmacy
Zhen Xiong Zhao, Xiao Hui Tang, Sheng Lu Jiang, Jia Qian Pang, Yu Bin Xu, Dan Dan Yuan, Ling Ling Zhang, Hui Min Liu, Qing Fan
Summary: This study established a high-purine diet-induced HN rat model and found that the pharmacokinetics of febuxostat showed accumulation in HN rats. Moreover, Astragaloside IV improved the pharmacokinetics of febuxostat in HN rats by regulating gut microbiota. These findings suggest that febuxostat might accumulate in HN patients, and Astragaloside IV could reverse the accumulation through gut microbiota regulation.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Dongqin Xia, Wenjie Li, Ce Tang, Juan Jiang
Summary: Cancer is increasing in developing countries with unsatisfactory outcomes from traditional cancer treatments. Traditional Chinese medicine (TCM) components, such as Astragaloside IV (AS-IV), have shown significant anticancer activities. AS-IV has various effects, including modulation of enzyme activities, cell cycle arrest, apoptosis and autophagy induction, and suppression of cancer progression. This article reviews the bioavailability, anticancer activity, and mechanism of AS-IV and provides suggestions for further research.
FRONTIERS IN PHARMACOLOGY
(2023)